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ABSTRACT 
Viewed in the context of ever-expanding conceptual boundaries for the diagnosis of 
bipolar disorder including the spectrum concept of DSM-IV, or even beyond (Akiskal 
and Pinto, 1999), it becomes obvious that lithium is the treatment of choice in a minority' 
of patients only (Bowden et al, 2000). This article reviews what additional benefit 
atypical antipsychotics may provide in patients with bipolar disorder. 
Due both to tradition and to the regulatory requirements in the USA (FDA) and 
European Union (EMEA), the main target of clinical trials with atypical antipsychotics 
has been typical manic disorder. More recently, a significant subgroup of atypical patients, 
e.g., with mixed states, marked psychosis, or rapid cycling, have participated in these 
studies to allow an estimation of the value of atypical antipsychotics in these conditions. 
For the purposes of filing applications for registration with the regulatory agencies, the 
existing evidence is probably weak, however; from a clinical perspective, it is important 
that most atypical antipsychotics have also been tested in combination treatments. 
Finally, first data are now available on long-term prophylactic efficacy of atypical 
antipsychotics. These combined efficacy data definitely support the use of atypical 
antipsychotics in bipolar disorder, and it is now the time to collect more experience 
with these substances in severely ill patients in clinical settings. 
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INTRODUCTION: USEFULNESS 
AND LIMITATIONS OF 
TYPICAL ANTIPSYCHOTICS 
The pnmary rationale to test atypical 
antipsychotics in bipolar disorder was the 
extensive clinical experience and established 
usefulness of classical antipsychotics in manic 
disorder. Due to their rapid sedative and 
antipsychotic effect these drugs proved to 
be useful in psychotic, agitated and hostile 
patients. 1 .specially in those patients not 
willing to take medication at all, the 
availability of intramuscular formulations 
was helptul. However, their disadvantages 
are obvious. A significant short-coming is 
the limited, if at all, efficacy in prophylaxis 
(Ahlfors et al, 1981; Ksparon et al, 1986). 
While treating mania with a classical 
antipsychotic drug, the clinician is afraid of 
the emergence of depressive symptoms 
(Harrow et al, 1994). The major 
disadvantages are the numerous side effects 
ranging from anticholinergic and cognitive 
side effects to typical extrapyramidal 
syndromes (IZPS) and, for worst, tardive 
dyskinesia. In up to 80% of bipolar patients 
acute HI'S have been observed (Briine, 
1999) whereas tardive dyskinesias are 
described in up to 35% of bipolar patients 
with long-term neuroleptic treatment 
(Mukhcrjee et al, 1986). 
Nevertheless, typical antipsychotics arc 
widely used in most parts of the world. In 
Germany, a census of the "Arzneimittcluber-
wachungin der Psychiatrie" (AMUP) Bayern, 
held in 1998, covered 275 acutely manic 
patients in different Bavarian state hospitals. 
In this study, an extensive use of typical 
antipsychotics has been noted. Of all manic 
patients, 83% received antipsychotics 
(Griinze and Dobmeier, 2002). In addition 
to this evidence, of clinical use, some 
controlled studies also support the efficacy 
of classical antipsychotics. As of 1 999, 9 
controlled studies comparing haloperidol to 
different standards have been published. In 
most of these, haloperidol was found to 
either beat the comparators or have at least 
equal efficacy (Griinze, 1999). None of 
these trials, however, had a placebo arm. 
Efficacy of haloperidol against placebo has 
only been shown recently in one 
monotherapy study (unpublished data, Astra 
Zeneca, on file) and one add-on study 
(Sachs et al, 2002b). Haloperidol, used as 
a comparator, was superior to placebo in 
both studies. 
Typical antipsychotics appear to be of 
special usefulness in severely manic and 
psychotic patients. The Northwick Park 
study (Johnstone et al, 1988), which 
compared pimozide, lithium and placebo in 
120 patients with functional psychosis found 
that pimozide was effective both for mania 
and psychotic symptoms, whereas lithium 
was effective on elevated mood only. With 
the broadening of the bipolar spectrum, 
psychotic symptoms have been 
accommodated fairly well within the scope 
of bipolar disorder as long as they do not 
dominate the clinical picture and overshadow 
the mood symptoms. Thus, a considerably 
higher number of patients will be diagnosed 
as bipolar disorder with psychotic symptoms, 
demanding treatment tliat is different from 
established mood stabilizers such as lithium. 
Atypical antipsychotics, combining probably 
the broader effectiveness of classical 
antipsychotics with improved tolerability may 
thus be appropriate for this new challenge. 
MONOTHERAPY WITH 
ATYPICAL ANTIPSYCHOTICS 
IN BLPOLAR DISORDER 
Derivatives of clozapine: 
Olanzapine and quetiapine 
Clozapine can be considered as the 
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father of atypical antipsychotics. Numerous 
case reports and several small investigator-
initiated trials support its antimanic as well 
as mild antidepressive and good prophylactic 
efficacy in bipolar patients (Frye et al, 
1998)). Thus, clozapine may be considered 
as a true mood stabiliser in contrast to 
typical antipsychotics; the latter may worsen 
depressive symptoms and appear not 
efficacious in prophylactic treatment. 
However, all these data are derived from 
small and often poorly controlled 
investigator-initiated trials. The large-scale 
methodologically unambiguous studies arc 
missing due to the lack of commercial 
interest and the potentially life threatening 
side effects of clozapine. 
This situation is clearly different for the 
new generation of atypical antipsychotics 
emerging since the beginning of the 1990s. 
Two of them, olanzapine and quctiapine, 
show receptor affinities relatively similar to 
that of clozapine. Like clozapine, their D, 
receptor occupancy level is relatively lower 
than their affinities for histaminergic (H ) 
receptors, 5-HT,A receptors (for olanzapine) 
and alphal receptors (for quctiapine). Both 
substances appear to be tolerated very well. 
Agranulocytosis docs not seems to be a 
f problem, however, the clinical experience is 
still limited. 
Olanzapine has shown significant 
superiority over placebo in two double-blind 
placebo-controlled monotherapy studies 
(Tohen et al, 1999; Tohen ct al, 2000). 
These studies had a duration of three and 
four weeks, respectively, applying a maximum 
dose of 20 mg/day of olanzapine. It is of 
interest, that especially in the 4-week study 
(Tohen et al, 2000) a relatively large number 
of patients with mixed states (43%) had 
been included. In both studies, more than 
50% of patients showed psychotic features 
also. It is of clinical importance that the 
improvement, as measured by the fall in the 
Young Mania Rating Scale (YMRS) scores, 
was not different in psychotic and non-
psychotic manic patients. Thus, improvement 
\ cannot be explained as a function of 
treatment of psychotic symptoms alone as, 
obviously, there are genuine effects on 
mood. No difference in efficacy measures 
could be found when coinparing patients 
with and without rapid cycling (Tohen ct 
al. 2000). In the same vein, patients with 
pure mania responded very similar to those 
with mixed symptomatology. In patients 
with marked depressive symptoms, there 
was also a significant improvement of the 
Hamilton Depressive Rating Scale (HAMD) 
during olanzapine treatment compared to 
placebo. Thus, although conducted for 
purposes of registration with regulatory 
authorities, these placebo-controlled data 
furnish clinically important information of 
a broader spectrum of efficacy for 
olanzapine. 
Every new potential mood stabiliser 
should not only beat placebo, but also have 
at least comparable efficacy to clinical 
standards. Two double-blind placebo-
controlled trials compared olanzapine with 
valproate in acute mania. In the trial of 
Tohen et al (2002a) olanzapine outperformed 
valproate on the primary outcome, the 
reduction of the YMRS after three weeks. 
However, this study may be criticized on the 
ground that valproate was likely to be 
under-dosed; only 87% of the manic patients 
reached sufficient plasma levels above 50 
ugl4. In a second study comparing 
olanzapine and valproate, Zajecka et al 
(2000) used higher doses of valproate (mean 
dose 2115 mg/day compared to 1401 mg/ 
day in the previous study). In this study, no 
significant difference between groups was 
found for YMRS reduction, however 
valproate appeared to have been better 
tolerable than olanzapine, on the whole. In 
times of increasing economic pressure, it 
may be also of note that the twelve week 
treatment costs for valproate were $541, and 
for olanzapine $1,080. These two trials are 
also a typical example that the outcome of 
trials, even considered as methodologically 
clean, clearly depends on dosing and other 
methodological issues (and finally on the 
sponsor!). 
For quctiapine, acute monotherapy data 
have not been published, so far. However, 
four large scale, placebo-controlled, double 
blind trials have just been concluded recently; 
three of these show a significant advantage 
of quctiapine. One trial had additionally 
included haloperidol as a comparator arm. 
The overall outcome after eight weeks was 
similar for quctiapine and haloperidol. 
Haloperidol showed a slightly faster onset 
of action whereas quetiapine was clearly 
better tolerated by the patients. For a more 
detailed review of these trials, one has to 
wait for the data to be published. 
Ziprasidone and risperidone 
These two atypical antipsychotics define 
themselves mainly by a very pronounced 
serotonergic component of action, both 
having a similar occupancy profile for die 
5-HT,A receptor. Ziprasidone has additional 
occupancy of the 5-H^A receptor. The 
dopaminergic D, receptor affinity is relatively 
stronger than with clozapine, quctiapine or 
olanzapine, which may also result in higher 
incidence of EPS when overdosed. 
Ziprasidone was tested for antimanic efficacy 
in a double-blind placebo-controlled 
multicentre study for the duration of three 
weeks, including 197 patients. The primary 
outcome parameter was the Mania Rating 
Scale, which consists of 10 items from the 
SRDS-C. Thus, this study had a design that 
was very similar to the pivotal study by 
Bowden et al (1994), comparing valproate 
against lithium and placebo. Ziprasidone 
was significantly superior to placebo starting 
from day 2 until day 21, the endpoint of 
the study (p<0.01). In the PANSS positive 
subscale, the secondary outcome parameter, 
ziprasidone also showed a significant effect 
on psychotic symptoms in these manic 
patients. 
For risperidone, double-blind placebo-
controlled monotherapy trials have been 
conducted but, as with quctiapine, are not 
published so far. We arc aware of two trials 
and both showed a significant antimanic 
response with risperidone as compared to 
the placebo arm (Janssen-Cilag, data on file). 
In one of these studies, conducted in India, 
a mean reduction of 21 points in the YMRS 
was observed, an antimanic response hardly 
ever seen in any controlled Phase III trial. 
However, approximately 50% of the patients 
had EPS also. One may argue that in 
general, the india patients have a lower body-
weight and that they might have been 
receiving a much higher dose as compared 
to US and European trials. 
Aripiprazole 
The chemical structure and the receptor 
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occupancy profile of Aripiprazole appear 
slightly different from other atypical 
antipsychotics. Aripiprazole is a partial 
agonist of D, and 5-UT A receptors. Its 
receptor binding affinity is high for D,, Dv 
5-1 IT, A, 5-1 IT,A and moderate for D,, 
alpha and II,, whereas it has no affinity for 
M . Three acute mania studies have been 
presented in scientific meetings as posters 
so far. They include two 3-week long studies 
against placebo and one 12-week long study 
against halopcridol. Aripiprazole was superior 
showing clear, significant separation from 
placebo at day 4 in one study, whereas in 
the other only a trend to higher efficacy was 
observed, mainly due to an extraordinary 
high placebo response rate of 38%. No 
difference in efficacy was observed in the 
halopcridol comparator study at endpoint, 
however, aripiprazole was clearly better 
tolerated. 
THE USEFULNESS OF 
ATYPICAL ANTIPSYCHOTICS 
IN COMBINATION 
TREATMENT 
Monotherapy trials arc needed to show 
unambiguous efficacy of a drug, even thugh 
combination treatment is the clinical reality, 
lor example, looking prospectively into the 
treatment of 258 patients of the Stanley 
foundation bipolar Network, it was noted 
that patients receive an average of 4.1 
medications for mood stabilisation (Post ct 
al, 2002). This trend towards combination 
treatment has also been demonstrated in 
other studies (l'rvc et al, 2000), including 
our own, conducted in the outpatient clinic 
in Munich as a part of the Stanley 
foundation Bipolar Network (Dittmann et 
al, 2002). I lowcvcr, until recently only a few 
controlled tnals were designed to test efficacy 
in combination treatment. Now we have 
three pivotal trials for olanzapine, risperidone 
and c|uctiapinc looking into this issue. 
In the study of Tohen et al. (2002b) 
patients were treated with cither valproate 
or lithium for acute mania. Those not 
showing sufficient response after three weeks 
were then randomised and treated in a 
double-blind fashion with either olanzapine 
(n = 220) or placebo (n=114) as an add-on. 
Olanzapine treated patients had a significant 
better outcome reflected by the YMRS. total 
score after six weeks of treatment. Again, 
a positive effect was also noted on the 
Hamilton Depression Rating Scale (HAM-
D) scores, especially in patients with mixed 
episodes with moderate or severe depressive 
symptoms. Concerning the YMRS, as with 
the placebo-controlled trials, olanzapine 
outperformed placebo also in patients with 
mixed mania and psychotic symptoms. 
For quetiapine, two studies using an add-
on design have been presented recendy. In 
a stud) by Sachs and colleagues (Sachs et 
al., 2002a) quetiapine was used as an adjunct 
treatment to lithium or valproate for 21 days 
in acutely manic patients. For the primary 
outcome criteria (YMRS) as well as for 
several secondary outcome criteria, 
including the CG1-BP, a significant 
advantage of quetiapine co-administration 
was observed. The incidence of adverse 
events was generally low and 
discontinuation due to these events was 
similar in both groups. 
The other study by Del Bello ct al 
(2002) tested the usefulness of quetiapine 
add-oii to valproate compared to placebo 
add-on for the treatment of acute mania 
in adolescents. Thirty patients were 
included in the study, and again the 
YMRS response rate was significantly 
greater in the valproate plus quetiapine 
group than in the valproate plus placebo 
group (87% versus 53%). Side effects were 
again scarce and not different from the 
placebo group. These findings arc of 
special importance as predominant 
symptoms of mania in adolescents arc 
often psychotic features, mixed states and 
rapid cycling (Carlson and Kashani, 2002; 
Findling et al, 2001), and so far few 
studies looked systematically into response 
rates and tolcrability in younger patients. 
Risperidone was also tested in two 
trials, one conducted in the US and one 
internationally, for its efficacy in manic or 
mixed episodes, applying an add-on design 
to previous mood stabilizer treatment. In 
the US study (Sachs et al. 2002b) lithium 
or valproate were allowed as mood stabilizers, 
whereas in the international study, 
carbamazepine could also be used. In 
addition, the US study had a halopcridol 
arm as an internal comparator. In the US 
study, both haloperidol and risperidone was 
statistically significantly superior to the add-
on placebo arm. Significance for 
risperidone was missed in the international 
study at first analysis. When excluding 
those patients who had been on 
carbamazepine, however, the international 
study was also able to show a significant 
advantage of risperidone add-on treatment 
compared to placebo (Yatham, 2000). 
From this study, it becomes obvious that 
combination treatment, including those 
with atypical antipsychotics, has to be 
conducted good skill keeping in mind the 
possibility of drug-drug interactions, for 
example on the level of the cytochrome 
P450. Both the US and the international 
study showed comparable efficacy for 
risperidone in patients exhibiting psychotic 
features or not. Side effects of risperidone 
were generally low, especially compared to 
haloperidol where a significantly higher 
incidence of EPS was observed. 
In general, there seems to be a consensus 
that the side effects with atypical 
antipsychotics are lower in comparison to 
typical antipsychotics. This is an important 
issue as it may determine patients' 
compliance. Weight gain is clearly a 
disadvantage of clozapine and olanzapine 
and less pronounced in risperidone and 
quetiapine, whereas ziprasidone is almost 
weight neutral. Weight gain is also associated 
with the increased risk of cardiovascular 
mortality, which is 1.6 rimes higher in 
treated bipolar patients and 2.1 times higher 
in untreated bipolar patients, compared to 
the general population (Angst ct al, 2002). 
Thus, when choosing the appropriate atypical 
antipsychotic for treating bipolar patients, 
this issue should be kept in mind and 
discussed openly with the patient. 
Effects of olanzapine on depressive 
symptoms in mixed patients have already-
been described previously for the 
monotherapy trials. In a recent combination 
treatment trial, olanzapine was compared 
against placebo and a combination of 
olanzapine and fluoxetine for the treatment 
of psychotic depression (Dube et al. 2002). 
In this double-blind 8 week trial, both 
olanzapine and the combination of 
olanzapine and fluoxetine separated 
significantly from placebo response in the 
Montgomery Asberg Depression Rating Scale 
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(MADRS), the primary outcome criterion. 
However, the time to response was clearly 
shortened by the combination of olanzapine 
and fluoxetine compared to both placebo 
and olanzapine monotherapy. Preliminary 
data for risperidone (Canuso, 2003) also 
support an antidepressant component of 
action. 
As suicidally obviously threatens bipolar 
depressed patients (Bottlender et al, 2000), 
it is of highly relevant clinically that better 
and faster acting treatments are developed 
for depressive episodes in bipolar patients. 
In this context, it is of interest that a recent 
study by Meltzer and colleagues (Meltzer et 
al, 2003) demonstrated antisuicidal effects 
of clozapine in schizophrenic and 
schizoaffective patients. 
MAINTENANCE TREATMENT: 
FIRST EXPERIENCES WITH 
ATYPICAL ANTIPSYCHOTICS 
Data on long-term efficacy of atypical 
antipsychotics in bipolar patients are still 
very limited. In a six month open study, 541 
patients received risperidone as an add-on 
treatment to previous mood stabiliser 
treatment (Victa et al, 2001). Both the mean 
YMRS and HAMD scores declined rapidly 
and remained on a low level in these bipolar 
I, bipolar II, or schizoaffective patients. 
For olanzapine, three controlled studies, 
one against placebo and two against 
comparators (valproate and lithium) furnish 
first evidence for a long-term prophylactic 
effect. 
In the placebo controlled study (Tohen, 
2002), patients in acute manic or mixed 
episodes of bipolar I disorder were treated 
with open-labelled olanzapine for a period 
of 6-12 weeks. Those achieving symptomatic 
remission (YMRS <=12 and HAMD-21 
<=8) were randomized to olanzapine 
(N=225) (5-20 mg/d) or placebo (N=136) 
for another 52 weeks of double-blind 
treatment. Whereas 80.1% of patients 
randomized to placebo suffered from at 
least one new episode during the following 
year, only 46.7 % of patients on olanzapine 
relapsed (p<0.001). Extending on the 
previously cited acute mania trial comparing 
olanzapine and valproate, Tohen et al (2001) 
conducted a 47 week continuation, double-
blind parallel group trial in those patients 
who responded to either valproate or 
olanzapine in acute mania. There was no 
significant difference in the number of 
manic relapses or in the median time to 
relapse between olanzapine and valproate 
treatments, however, there was a tendency 
to have fewer fresh manic episodes with 
olanzapine. 
The prophylactic antimanic efficacy of 
olanzapine is also supported by a recently 
presented 12 months double blind trial 
comparing olanzapine and lithium in patients 
who were euthymic at the beginning of the 
study (Tohen et al, 2002c). Olanzapine 
outperformed lithium both in the survival 
analysis and in the percentage of patients 
who relapsed into mania. No difference was 
observed with respect to the percentage of 
patients who experienced a depressive 
relapse. Thus, olanzapine may constitute an 
alternative to lithium in prophylactic 
treatment for patients who have 
predominandy manic episodes. If preventing 
new depressed episodes is of similar clinical 
importance, combination therapies, e.g. with 
lamotrigine, should be considered (Goodwin 
et al, 2002). 
CONCLUSIONS 
Atypical antipsychotics are an emerging 
treatment for bipolar patients as summarized 
in the Table 1. Both controlled and real 
world studies with risperidone, olanzapine, 
ziprasidone, quetiapine and aripiprazole 
showed efficacy in treating acute mania. 
Atypical antipsychotics seem also to improve 
depressive symptoms or at least do not 
worsen depression as conventional 
antipsychotics may do. Controlled data, 
though preliminary in nature, also support 
prophylactic efficacy especially for olanzapine 
TABLE I: Overview on the levels of demonstrated efficacy of selected atypical antipsychotics in bipolar disorder. All grading is 
subject to the knowledge of the authors as of March 2003. 
Substance 
Aripiprazole 
Clozapine 
Olanzapin 
Quetiapine 
Risperidone 
Ziprasidone 
Euphoric 
mania 
+ + 
+ 
+ + + 
+ + 
+ + + 
+ + + 
Mixed 
mania 
+ + 
+ 
+ + + 
+ + 
++ 
+ + + 
Bipolar 
depression 
0 
+ 
+ 
+ 
+ 
0 
Rapid 
cycling 
0 
+ 
+ + + 
+ 
+ 
0 
Maintenance 
in general 
0 
+ 
++ 
0 
+ 
0 
Prophylaxis 
of Euphoric 
mania 
0 
+ 
++ 
0 
+ 
0 
Prophylaxis 
of mixed 
mania 
0 
+ 
++ 
0 
+ 
0 
Prophylaxis 
of Bipolar 
depression 
0 
+ 
+ + 
0 
+ 
0 
Prophylaxis 
of Rapid 
cycling 
0 
+ 
0 
+ 
+ 
0 
+++ Efficacy in double-blind, controlled studies, published in peer-reviewed journal 
+ + Efficacy in double-blind, controlled studies data published as abstract and presented on conferences 
+ Efficacy in open studies, no double-blind controlled studies published so far 
0 To the authors knowledge, no studies in bipolar disorder conducted so far 
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and partially also for risperidonr. For 
olanzapine, the suppression of manic 
episodes seems to be the more pronounced 
mode of action. However, we definitely 
need more controlled data, especially placebo 
controlled data, for all atypical antipsychotics 
with regard to long-term efficacy and 
prophylactic treatmtent. A main advantage 
of atypical antipsychotics is their relatively 
good tolerability, at least compared to 
conventional antipsychotics. This is definitely 
a key issue for long-term compliance of 
patients. Besides studying long-term efficacy 
of atypical antipsychotics in controlled 
studies, it is now also of importance to have 
more large scale naturalistic studies in clinical 
populations of bipolar patients. Comorbidity 
in bipolar patients is the rule, rather than 
exception. Atypical presentations are at least 
as common as classical clinical pictures. 
Thus, large scale simple trials with atypical 
antipsychotics will broaden our knowledge 
about the real world clinical effectiveness of 
this class of agents and also give us more 
information about long-term safety of these 
novel compounds. 
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